S
Susan Wyllie
Researcher at University of Dundee
Publications - 84
Citations - 3771
Susan Wyllie is an academic researcher from University of Dundee. The author has contributed to research in topics: Trypanosoma brucei & Trypanothione. The author has an hindex of 32, co-authored 72 publications receiving 3061 citations. Previous affiliations of Susan Wyllie include East Tennessee State University James H. Quillen College of Medicine & University of Edinburgh.
Papers
More filters
Journal ArticleDOI
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Mark C. Field,David Horn,Alan H. Fairlamb,Michael A. J. Ferguson,David W. Gray,Kevin D. Read,Manu De Rycker,Leah S. Torrie,Paul G. Wyatt,Susan Wyllie,Ian H. Gilbert +10 more
TL;DR: The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.
Journal ArticleDOI
Dual action of antimonial drugs on thiol redox metabolism in the human pathogen leishmania donovani
TL;DR: It is shown that trivalent antimony (SbIII) interferes with trypanothione metabolism in drug-sensitive Leishmania parasites by two inherently distinct mechanisms, which combine to profoundly compromise the thiol redox potential in both amastigote and promastigotes stages of the life cycle.
Journal ArticleDOI
Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects
Stephen Patterson,Susan Wyllie +1 more
TL;DR: Two nitro drugs are currently used in the treatment of trypanosomatid diseases and several new nitroaromatics are being developed against the trypano-somatica diseases.
Journal ArticleDOI
The Anti-Trypanosome Drug Fexinidazole Shows Potential for Treating Visceral Leishmaniasis
Susan Wyllie,Stephen Patterson,Laste Stojanovski,Frederick R. C. Simeons,Suzanne Norval,Robert Kime,Kevin D. Read,Alan H. Fairlamb +7 more
TL;DR: Fexinidazole, a drug currently in phase 1 clinical trials for treating African trypanosomiasis, shows promise for treating visceral leishmaniasis, and is comparable to that of drugs currently in clinical use against this deadly tropical disease.
Journal ArticleDOI
Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.
Manu De Rycker,Irene Hallyburton,John Thomas,Lorna Campbell,Susan Wyllie,Dhananjay Joshi,Scott Cameron,Ian H. Gilbert,Paul G. Wyatt,Julie A. Frearson,Alan H. Fairlamb,David W. Gray +11 more
TL;DR: It is concluded that the intramacrophage assay is more suited as a primary hit-discovery platform than the current form of axenic assay, and how modifications to theAxenic assay may render it more suitable for hit-Discovery is discussed.